Hereditary Transthyretin Amyloidosis (HATTR)
Market
Hereditary Transthyretin Amyloidosis (HATTR)
Market Scope: Industry Analysis, Market Size, Growth, Trends Till 2031
Request Sample Report
Hereditary Transthyretin Amyloidosis (HATTR) Market
Size and Growth
Hereditary Transthyretin Amyloidosis (HATTR) is an emerging focus in the biopharmaceutical sector, with significant growth projected. The global market is valued at approximately $2 billion, driven by increasing diagnoses and innovative therapies. Competitive landscapes reveal active pipeline developments, policy advancements, and heightened awareness among healthcare professionals, indicating a dynamic market evolution.
Request Sample Report
Companies Covered
(Covid 19 Impact Covered)
◍ Pfizer
◍ Alnylam Pharmaceuticals
◍ Akcea Therapeutics
◍ Prothena
◍ Lonis Pharmaceuticals
◍ Eidos Therapeutics
◍ Corino Therapeutics Inc
The HATTR market includes key players like Pfizer, Alnylam Pharmaceuticals, and Akcea Therapeutics. Their therapies, such as Onpattro and Tegsedi, enhance treatment options. By innovating and increasing awareness, these companies drive market growth. Sales figures: Alnylam (2022 revenue: ~$350M), Pfizer (2022 revenue: ~$2.7B from rare disease portfolio).
Request Sample Report
Market Segmentation
By Application
Hospital
Clinic
Others
Request Sample Report
By Product
Oral
Subcutaneous Injection
Others
Market Growth
Request Sample Report
$ X Billion USD
